Wuxi Xdc Cayman Inc. (中国)

The Company was incorporated in the Cayman Islands as an exempted company with limited liability on December 14, 2020.
The Company is an investment holding company. During the Track Record Periods, the Company's subsidiaries were involved in the following principal activities in the People's Republic of China : Research services on FFS basis and Research services on full-time- equivalent (“FTE”) basis.
HISTORY
The key milestones on development to date are set out below :
2013 Wuxi XDC Cayman Inc. signed the first ADC CMC contract and commenced the ADC CRDMObusiness internally within the WXB Group's BCD
business unit
2016 The Company was completed the first NMPA IND filing by the customers
2018 The Company was established a separate and dedicated ADC facility, DP3, in Wuxi, the PRC
2019 The Company was established the proprietary WuXiDAR4 technology platform, further enriching portfolio of the company of conjugation technologies.
The Company was commenced partnership with first EU customer, NBE-Therapeutics, a Swiss biotech company subsequently acquired by
Boehringer Ingelheim, on the development and manufacturing of NBE-Therapeutics' first ADC product demonstrating our strong R D capability and
service quality.
The Company ADC facility, DP3, in Wuxi, the PRC, commenced GMP manufacturing.
2020 The Company was obtained the drug manufacturing license from the NMPA.
The Company was incorporated in the Cayman Islands.
2021 The Company was presented with the “Bioprocessing Excellence in Antibody and ADC Therapeutics Manufacturing in the Greater China Region”
award by the IMAPAC.
The Company entered into equity subscription agreement with WuXi Biologics and STA Pharmaceutical in relation to subscription of Shares,
upon completion of which the Company were owned as to 60 by WuXi Biologics and 40 by STA Pharmaceutical, respectively.
The Company was entered into agreements for the transfers of BCD business unit and XDC Wuxi and the acquisition of the Payload Linker
Business to strengthen our capabilities.
2022 Shanghai facilities began operations, greatly improving our discovery and PD capacities.
The Company was received the runner up prize in the “Best Contract Manufacturing Provider” category at the 2022 World ADC Awards.
The Company was established XDC Singapore, an important step in the implementation of “global dual sourcing” strategy and to build a
manufacturing base in Singapore.
2023 The Company s new ADC facility in Wuxi formally commenced operations, strengthening in-house discovery and development capabilities and
manufacturing capacity.
Wuxi XDC Cayman Inc. won the “Best Contract Development Manufacturing Organization (CDMO)” prize at the 2023 World ADC Awards.